The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Micro-Abstract Colorectal cancer patients with KRAS wild-type tumours are often treated with anti-epithelial growth factor receptor (EGFR) antibodies with or without standard cytotoxic regimens. Unfortunately, not all of them seem to benefit from the targeted therapy, highlighting the need of findin...

Full description

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2013-12, Vol.12 (4), p.267-274.e2
Main Authors: Strimpakos, Alexios, Pentheroudakis, George, Kotoula, Vassiliki, De Roock, Wendy, Kouvatseas, George, Papakostas, Pavlos, Makatsoris, Thomas, Papamichael, Demetris, Andreadou, Anna, Sgouros, Joseph, Zizi-Sermpetzoglou, Adamantia, Kominea, Athina, Televantou, Despina, Razis, Evangelia, Galani, Eleni, Pectasides, Dimitrios, Tejpar, Sabine, Syrigos, Konstantinos, Fountzilas, George
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - metabolism
Adenocarcinoma - mortality
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - analysis
Cetuximab
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - metabolism
Colorectal Neoplasms - mortality
Ephrin-A2 - metabolism
Female
Gastroenterology and Hepatology
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Receptor, Epidermal Growth Factor - metabolism
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Colorectal cancer patients with KRAS wild-type tumours are often treated with anti-epithelial growth factor receptor (EGFR) antibodies with or without standard cytotoxic regimens. Unfortunately, not all of them seem to benefit from the targeted therapy, highlighting the need of finding more predictive and prognostic biomarkers. The current study on 226 patients with advanced colorectal cancer (mCRC) treated with cetuximab based therapy showed that high EphA2 receptor expression is significantly associated with poor outcome. More research is required to define EphA2 expression exact predictive and prognostic role.
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2013.07.001